Home  |  Contact

UniProtKB/Swiss-Prot P11362: Variant p.Pro745Ser

Fibroblast growth factor receptor 1
Gene: FGFR1
Variant information

Variant position:  745
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Proline (P) to Serine (S) at position 745 (P745S, p.Pro745Ser).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (P) to small size and polar (S)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In HH2.
Any additional useful information about the variant.



Sequence information

Variant position:  745
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  822
The length of the canonical sequence.

Location on the sequence:   CTNELYMMMRDCWHAVPSQR  P TFKQLVEDLDRIVALTSNQE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 22 – 822 Fibroblast growth factor receptor 1
Topological domain 398 – 822 Cytoplasmic
Domain 478 – 767 Protein kinase
Modified residue 730 – 730 Phosphotyrosine; by autocatalysis
Alternative sequence 62 – 822 Missing. In isoform 3.
Alternative sequence 151 – 822 Missing. In isoform 16.
Alternative sequence 392 – 822 Missing. In isoform 17 and isoform 18.
Alternative sequence 663 – 822 Missing. In isoform 2, isoform 5, isoform 7, isoform 9, isoform 11 and isoform 13.
Mutagenesis 755 – 755 D -> V. Abolishes interaction with PLCG1.


Literature citations

Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients.
Sato N.; Katsumata N.; Kagami M.; Hasegawa T.; Hori N.; Kawakita S.; Minowada S.; Shimotsuka A.; Shishiba Y.; Yokozawa M.; Yasuda T.; Nagasaki K.; Hasegawa D.; Hasegawa Y.; Tachibana K.; Naiki Y.; Horikawa R.; Tanaka T.; Ogata T.;
J. Clin. Endocrinol. Metab. 89:1079-1088(2004)
Cited for: VARIANT HH2 SER-745;

Gonadotrophin therapy in Kallmann syndrome caused by heterozygous mutations of the gene for fibroblast growth factor receptor 1: report of three families: case report.
Sato N.; Hasegawa T.; Hori N.; Fukami M.; Yoshimura Y.; Ogata T.;
Hum. Reprod. 20:2173-2178(2005)
Cited for: VARIANTS HH2 ARG-687 AND SER-745;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.